-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Neutral on GoodRx Holdings, Raises Price Target to $3.75

Benzinga·08/13/2026 21:20:04
Listen to the news
UBS analyst Kevin Caliendo maintains GoodRx Holdings (NASDAQ:GDRX) with a Neutral and raises the price target from $2.5 to $3.75.